Skip to main content
OpenTrials
Completed

NCT Number: NCT06533683

Effects of Kinesio Taping and Extracorporeal Shock Wave Therapy in the Calcaneal Spur

The term "heel pain" is used to describe a common, painful condition that is localized in the plantar part of the heel and worsens when weight is placed on the heel. Patients with heel pain are more likely to have thickened plantar fascia, abnormal plantar fascia tissue, thicker plantar heel fat pad, and calcaneal spur. Calcaneal spurs are bony protrusions that typically occur just in front of the medial calcaneal tuberosity. Systemic medical treatments, physical therapy agents, exercise and local injections are often applied for heel pain caused by plantar fasciitis and calcaneal spur.

This study is to examine the effects of ESWT and kinesio taping on pain and other clinical outcomes in patients with calcaneal spurs.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Şişli Hamidiye Etfal Training and Research Hospital

Istanbul, Turkey (Türkiye)

About this study

The responses of patients who underwent ESWT or kinesio taping due to calcaneal spur before and after treatment will be compared. Pain, functionality and quality of life are the clinical parameters compared.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18 years and over with heel pain
  • A calcaneal spur seen on foot radiographs

Exclusion criteria

  • Those who had received a steroid injection into the heel within the past three months
  • Those who had experienced trauma or surgery to the foot and ankle within the past six months
  • Those with a rheumatic disease affecting the foot and ankle (e.g., spondyloarthritis)
  • Those with open wounds or infections in the area to be treated with lesions.

Treatment and study plan

Primary outcomes

  1. Pain level before treatment and 3rd month after treatment

    Time frame: From enrollment to the end of treatment at 3rd month

    Pain level will be evaluated with the Numerical Rating Scale. (minimum: 0, maximum: 10)

Secondary outcomes

  1. Assessment of heel sensitivity

    Time frame: From enrollment to the end of treatment at 3rd month

    It will be evaluated with the Heel Tenderness index. (0=no pain; 1=painful; 2=painful and whines; 3=painful, whines, and withdraws)

  2. Assessment of functionality

    Time frame: From enrollment to the end of treatment at 3rd month

    Foot Function Index was used. The FFI consists of 23 items divided into 3 subscales that quantify the impact of foot pathology on pain, disability, and activity limitation in patients. Pain, disability, and activity limitation subscale scores range from 0 to 100.

  3. Assessment of quality of life

    Time frame: From enrollment to the end of treatment at 3rd month

    The 12-item short-form health survey (SF-12) quality of life scale was used to evaluate general quality of life. It was presented as a physical component score (PCS) and mental component score (MCS). Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.

Sponsors and collaborators

Lead sponsor

Sisli Hamidiye Etfal Training and Research Hospital

Other

Registry information

Official study title

Effects of Kinesio Taping Versus Extracorporeal Shock Wave Therapy on Pain in the Treatment of Calcaneal Spur: A Retrospective Clinical Study

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Aug 1, 2024
Registry last updated
Aug 1, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.